Ge discovery 710

Available 68Ga-DOTATATE PET/CT and PET/MR scans were reviewed by a nuclear medicine physician and radiologist (GBJ) and a Krenning score was applied. Briefly, Krenning score is a qualitative measure of relative uptake of 68Ga-DOTATATE in tumors versus the physiologic uptake in the internal organs of the liver and spleen, with a Krenning score of 1 being negative and tumor activity far below liver activity, a Krenning score of 2 being mildly positive with activity slightly less than liver, a Krenning score of 3 being positive with activity higher than liver, and a Krenning score of 4 being very positive with activity above spleen. Scans were performed on GE Discovery 710, GE Discovery MI and Siemens Vision 600 PET/CT or GE Signa PET/MR scanners. Uptake was 60 minutes plus or minus 5 minutes in all patients, and the injected dose was 5.2 mCi 68Ga-DOTATATE IV +/- 10% IV.

Rest and pharmacological stress PET-MPI studies utilizing [⁸²Rb]Cl were performed with a Biograph 64 PET/CT scanner (Siemens Healthcare, Erlangen, Germany) or GE Discovery 710 (GE Healthcare, Waukesha, Wisconsin) scanners. Directly prior to the injection of weight-based dose of 925–1,850 MBq (25–50 mCi) of [⁸²Rb]Cl, a 6-min rest list-mode acquisition was initiated. Regadenoson was utilized to induce pharmacological stress, and a 6-min stress list-mode acquisition was initiated at the same time along with the [⁸²Rb]Cl infusion of the same dose as for the rest scan. As previously detailed, before each rest and stress PET scanning, a low-dose CT scan was obtained for attenuation correction [11 (link)].

The Department of Medical Imaging and Physiology at Skåne University Hospital in Lund/Malmö, Kristianstad County Hospital, and Växjö County Hospital, Sweden, conducted the FDG-PET/CT scans. The systems used were Philips Gemini TF (Philips Medical Systems, Cleveland, OH), GE Discovery 690 (GE Healthcare, Milwaukee, WI, USA), GE Discovery 710 (GE Healthcare, Milwaukee, WI, USA) or GE Discovery MI (GE Healthcare, Milwaukee, WI, USA). To decrease the concentration of FDG in the urinary tract, a diuretic (intravenous furosemide 20 mg) was administrated at the same time as ¹⁸F-FDG (4 MBq/kg), and imaging was performed 120 min after radiopharmaceutical administration (Anjos et al. 2007 (link)). The patients were scanned from the inguinal region to the base of the skull. CT images were acquired for attenuation correction and anatomic correlation of the PET images. A diagnostic CT with intravenous and oral contrast or a low-dose CT without contrast was performed. A low-dose CT was chosen in 51/157 (32%) of the patients when a previous diagnostic CT was performed within 4 weeks of the FDG-PET/CT scan, and thus, no direct comparison between the CT and FDG-PET/CT was feasible. Instead, the outcome measure preoperative lymph node stage in the current study was derived from a reassessment and visual analyses by one nuclear medicine physician and one radiologist at the MDT prior to RC.

All patients underwent whole-body
¹⁸F-FDG PET/CT in the Department of Nuclear Medicine, the Hospital 108. PET/CT scan was performed, using GE Discovery 710 (GE Healthcare, Milwaukee, Wisconsin, United States), according to the European Association of Nuclear Medicine guidelines, version 2.0.
24 (link)
Patients should be fasted at least 4 hours, and blood sugar was measured before injection of
¹⁸F-FDG. The PET/CT study schedule was postponed when glucose level higher than 11 mmol/L (about 200 mg/dL). Afterward, the patients rested in the waiting room before intravenous injection of 2.5 MBq/kg body weight (±10%) of
¹⁸F-FDG. The parameters of the low dose CT scan were as follows: 120 kVp, modulated milliampere-seconds (mAs), the helical slice thickness of 3.75 mm, and 0.5 s/rotation. PET images were reconstructed using an iterative algorithm with attenuation correction with CT.